HomeCompareMNKPF vs GBDC

MNKPF vs GBDC: Dividend Comparison 2026

MNKPF yields 11.59% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.73M in total portfolio value
10 years
MNKPF
MNKPF
● Live price
11.59%
Share price
$17.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.0K
Annual income
$2,392.79
Full MNKPF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — MNKPF vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNKPFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNKPF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNKPF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNKPF
Annual income on $10K today (after 15% tax)
$985.51/yr
After 10yr DRIP, annual income (after tax)
$2,033.87/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,928,840.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNKPF + GBDC for your $10,000?

MNKPF: 50%GBDC: 50%
100% GBDC50/50100% MNKPF
Portfolio after 10yr
$10.41M
Annual income
$8,195,828.10/yr
Blended yield
78.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

MNKPF
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNKPF buys
0
GBDC buys
0
No recent congressional trades found for MNKPF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNKPFGBDC
Forward yield11.59%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$43.0K$20.78M
Annual income after 10y$2,392.79$16,389,263.41
Total dividends collected$17.6K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MNKPF vs GBDC ($10,000, DRIP)

YearMNKPF PortfolioMNKPF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$11,859$1,159.42$12,490$1,790.28$631.00GBDC
2$13,975$1,285.05$16,522$3,157.73$2.5KGBDC
3$16,368$1,415.19$23,578$5,898.68$7.2KGBDC
4$19,063$1,549.12$37,115$11,886.75$18.1KGBDC
5$22,083$1,686.15$66,136$26,423.57$44.1KGBDC
6$25,455$1,825.53$137,257$66,491.44$111.8KGBDC
7$29,203$1,966.57$341,734$194,868.54$312.5KGBDC
8$33,356$2,108.56$1,050,788$685,133.02$1.02MGBDC
9$37,942$2,250.84$4,099,314$2,974,971.01$4.06MGBDC
10$42,991$2,392.79$20,775,530$16,389,263.41$20.73MGBDC

MNKPF vs GBDC: Complete Analysis 2026

MNKPFStock

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.

Full MNKPF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this MNKPF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNKPF vs SCHDMNKPF vs JEPIMNKPF vs OMNKPF vs KOMNKPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.